Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18230248 | 0.91 | CES2 (0.53) | HPGDRECQLALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL18230433 | 0.84 | MAOB (0.51) | HPGDRECQLALDH1A1KDM4EHSD17B10 | |
| SCHEMBL18230251 | 0.84 | GRM4 (0.47) | ALDH1A1CES2CES1LMNANAPRT | |
| SCHEMBL38661644 | 0.81 | CTNNB1 (0.44) | HPGDRECQLALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL9843696 | 0.81 | HPGD (0.48) | HPGDRECQLALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5443678 | 0.78 | HTR3E (0.44) | ALDH1A1SMN1; SMN2KMT2ACES2CES1 | |
| SCHEMBL5443676 | 0.78 | HTR3E (0.44) | ALDH1A1SMN1; SMN2KMT2ACES2CES1 | |
| SCHEMBL10571875 | 0.76 | HPGD (0.64) | HPGDRECQLALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31098460 | 0.76 | SMN1; SMN2 (0.47) | HPGDRECQLALDH1A1KDM4EHSD17B10 | |
| SCHEMBL18236306 | 0.76 | L3MBTL1 (0.46) | ALDH1A1KDM4EHSD17B10SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-10087173-B2 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | BARUCH S. BLUMBERG INSTITUTE | 2018-10-02 | — | — | US | disclosed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | BARUCH S. BLUMBERG INSTITUTE | 2014-09-04 | — | — | US | disclosed |
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | BARUCH S. BLUMBERG INSTITUTE | 2014-09-04 | — | — | US | disclosed |
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | BARUCH S. BLUMBERG INSTITUTE | 2014-09-04 | — | — | US | disclosed |
| EP-0697404-B1 | New enantiomerically pure pyridyl cycloalkylethyl amines and their salts as well as process for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-04-18 | — | — | EP | disclosed |
| US-5767279-A | Enantiomerically pure pyridylcycloalkylethylamines and the salts thereof and processes for preparing them | BOEHRINGER INGELHEIM GMBH (DE) | 1998-06-16 | — | — | US | disclosed |
| EP-0697404-A1 | New enantiomerically pure pyridyl cycloalkylethyl amines and their salts as well as process for their production | BOEHRINGER INGELHEIM KG (DE) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087173-B2 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | HDGF, HCCS, BCAT1 | HPGD 2172/4885RECQL 2346/4885ALDH1A1 951/4885 |
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | HCCS, BCAT1, AADAT | HPGD 1961/4885RECQL 1484/4885ALDH1A1 1067/4885 |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | HDGF, HCCS, BCAT1 | HPGD 2172/4885RECQL 2346/4885ALDH1A1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.